Rectal cancer blood test study before surgery
Part of Cancer, Digestive system clinical trials.
This trial is studying a blood test (CTC) for people with rectal cancer that hasn't spread to other parts of the body. It aims to see how the test relates to treatment outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have rectal cancer that is within about 5 inches (12 cm) from the anal opening.
- Your cancer is stage II or III (it has not spread to distant organs like the liver or lungs).
- An MRI shows the tumor can be removed with a clear margin (no cancer left behind).
- You are healthy enough for surgery (ASA physical status I, II, or III).
- You have no other active cancers and do not need emergency surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
This study follows real-world treatment of locally advanced rectal cancer (cancer that has grown into nearby tissues but hasn't spread to distant organs) in patients who receive chemotherapy and/or radiation before surgery. Researchers track how different treatment approaches work to help improve outcomes.
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
This study uses a special blood test to look for traces of tumor DNA (ctDNA) and compares it with information from your original tumor tissue or a new biopsy. It’s done in people with locally advanced rectal cancer who are going to receive standard chemotherapy and radiation, aiming to better track the cancer’s behavior.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.